海南发展（002163）(002163.SZ)公告，公司控股子公司海控三鑫(蚌埠)新能源材料有限公司(简称"海控 三鑫")于近期对550吨窑炉及5条深加工生产线进行停窑减产。公告称，海控三鑫停窑减产，有利于降低 运营成本，减少公司经营亏损。 ...

Overview of the Merger - The company has approved a merger between its wholly-owned subsidiaries, Chongqing Jinxin Frequency Control Electronics Co., Ltd. and Chongqing Taiqing Electronics Co., Ltd., to optimize resource allocation, reduce operational costs, and improve management efficiency [1][2][3] - After the merger, Chongqing Jinxin will continue to operate, while Chongqing Taiqing will be legally dissolved, with all debts and assets transferred to Chongqing Jinxin [1][3] Details of the Merging Entities - **Chongqing Jinxin Frequency Control Electronics Co., Ltd.**: Established on March 26, 2020, with a registered capital of 100 million yuan, it specializes in manufacturing electronic components and medical masks [1][2] - **Chongqing Taiqing Electronics Co., Ltd.**: Established on May 28, 2018, with a registered capital of 20 million yuan, it focuses on the research, production, and sales of quartz crystal frequency components. As of December 31, 2024, it reported total assets and a net loss of approximately 8 million yuan [2][3] Impact of the Merger - The merger is expected to enhance resource allocation, lower operational costs, and improve management efficiency, aligning with the company's development strategy [3] - The merger will not have a substantial impact on the company's normal operations and does not constitute a related party transaction or a major asset restructuring, ensuring the protection of all shareholders' interests, especially minority shareholders [3]

证券代码：688621 证券简称：阳光诺和 公告编号：2025-042 北京阳光诺和药物研究股份有限公司 关于注销孙公司南京诺和欣医药科技有限公司暨关 联交易的议案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 北京阳光诺和药物研究股份有限公司（以下简称"公司"或"阳光诺 和"）拟注销控股孙公司南京诺和欣医药科技有限公司（以下简称"诺和欣"）。 ? 赵凌阳先生在 2019 年 1 月-2024 年 9 月期间历任阳光诺和董事会秘书、 董事、财务总监，且持有诺和欣 18%股权。本次拟注销控股孙公司事项构成关联 交易，不构成重大资产重组。 ? 根据《上海证券交易所科创板股票上市规则》的有关规定，过去 12 个月 内，公司与同一关联人发生的关联交易，累计金额未达到占公司最近一期经审计 总资产或市值 1%以上的交易，且超过 3000 万元，本次关联交易金额在董事会审 批权限之内，无需提交股东会审议。 公司于 2025 年 5 月 12 日召开第二届董事会第十九次会议，审议通过了《关 于注销孙公司南京诺和欣医药 ...